6 Potential Changes to Prescription Drug Costs Under Trump’s Presidency
The high cost of prescription drugs remains a pressing concern for Americans, with many finding prices unreasonable. A survey by KFF revealed that while 65% of adults find it relatively easy to pay for their prescriptions, those on multiple medications often struggle. A significant factor contributing to these high costs, according to public opinion, is the profit-driven approach of pharmaceutical companies. As Americans evaluate potential policy changes under a Trump presidency, the future of prescription drug costs is under intense scrutiny.
“We could see a complete reform of the Medicare/Medicaid system,” noted Lindsay Dymowski, president of Centennial Pharmacy Services.
From Medicare price negotiations to international trade policies, here’s an in-depth look at six possible changes that could reshape the prescription drug pricing landscape:
1. Medicare Price Negotiation
The Medicare drug price negotiation program—introduced as part of the Inflation Reduction Act—faces an uncertain future. While the Biden administration aimed to expand negotiations to include up to 50 drugs annually, Trump’s approach could shift control to the federal government, according to The New York Times. Although Trump has expressed support for Medicare to negotiate prices in certain circumstances, the details remain ambiguous.
“Better quantity and quality choices are possible,” said Dr. Taher Saifullah, founder of the Spine & Pain Institute Los Angeles. “This often leads to lower prices, especially for seniors who rely on multiple prescriptions.”
2. Price Transparency Regulations
Despite his reputation for deregulation, Trump’s administration may introduce price transparency measures. These regulations could compel pharmacies to disclose wholesaler pricing, fostering more competitive prices for consumers.
“Pharmacies often struggle to ensure they’re getting the best deals on medications due to individualized contracts,” explained Dymowski. “Transparency could drive prices down at the pharmacy counter, but the overall industry impact remains to be seen.”
3. Rebate System Overhaul
The current rebate system—involving manufacturers, pharmacy benefit managers (PBMs), and health plans—could face significant reforms. While rebates often lower costs for insurers, the savings rarely reach patients directly.
“Rebates reduce insurer costs, but patients seldom benefit because the rebates are processed after payments are made,” Dymowski said.
During his first term, Trump proposed transferring $29 billion in rebates from PBMs to consumers under Medicare Part D, according to the Council for Informed Drug Spending Analysis. Renewed efforts in this area could mean more direct savings for patients at the pharmacy counter.
4. Medicare/Medicaid Reform
Trump’s presidency might bring changes to Medicare and Medicaid—including revisiting the $2,000 out-of-pocket spending cap introduced in January 2025. Parts of the Inflation Reduction Act could also face potential repeal or modification.
“Implementing a maximum spending limit could stabilize costs for beneficiaries,” said Dymowski. “This could improve medication adherence by reducing financial barriers at the point of purchase.”
5. Expedited FDA Approval Process
A hallmark of Trump’s previous term was prioritizing expedited FDA approvals, particularly for generic drugs. Although many approved generics were slow to reach consumers, the push for faster market entry could continue.
“Trump was very pro-expediting the FDA approval process during his last term,” Dymowski explained. “Regulatory changes might make generics more accessible, increasing competition and potentially driving prices down.”
This focus on generics could lead to a more competitive pharmaceutical market, offering patients cost-effective alternatives to brand-name medications.
6. International Trade Policies
Trump’s international trade strategies could significantly impact drug pricing and importation policies. High tariffs on imported goods—including medications and raw materials—might drive prices up. However, encouraging domestic production could yield long-term savings.
“If American companies start producing medications domestically and sourcing ingredients locally, prices could decrease,” Dymowski said.
Dr. Saifullah added, “Allowing drug imports from Canada or other countries with lower medication costs could alleviate price burdens. However, safety and quality must be carefully balanced with affordability.”
What Lies Ahead?
Changes to prescription drug costs under Trump’s presidency remain speculative but could bring profound shifts to pricing structures, accessibility, and affordability. Whether through Medicare reforms, transparency initiatives, or international trade adjustments, the potential for significant cost reductions—or increases—warrants close attention.
For Americans reliant on multiple prescriptions, these changes could profoundly impact both healthcare spending and overall well-being.